$197 Million is the total value of Corriente Advisors, LLC's 16 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 112.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MAXR | Buy | MAXAR TECHNOLOGIES INC | $49,183,000 | +44.1% | 1,972,061 | +3.8% | 24.94% | +12.8% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $29,226,000 | +27.0% | 300,000 | +103.4% | 14.82% | -0.6% |
| CUE | Buy | CUE BIOPHARMA INC | $21,634,000 | +33.7% | 1,437,445 | +117.8% | 10.97% | +4.7% |
| Buy | APTOSE BIOSCIENCES INC | $20,580,000 | +17.7% | 3,430,000 | +23.8% | 10.44% | -7.9% | |
| TFFP | New | TFF PHARMACEUTICALS INC | $19,556,000 | – | 1,058,823 | +100.0% | 9.92% | – |
| CRDF | Buy | CARDIFF ONCOLOGY INC | $12,913,000 | +1386.0% | 910,000 | +424.9% | 6.55% | +1063.1% |
| REPL | Buy | REPLIMUNE GROUP INC | $11,798,000 | -2.1% | 512,500 | +5.7% | 5.98% | -23.4% |
| BYND | New | BEYOND MEAT INC | $5,812,000 | – | 35,000 | +100.0% | 2.95% | – |
| SPCE | New | VIRGIN GALACTIC HOLDINGS INC | $4,808,000 | – | 250,000 | +100.0% | 2.44% | – |
| VFF | New | VILLAGE FARMS INTL INC | $4,321,000 | – | 943,396 | +100.0% | 2.19% | – |
| DDOG | New | DATADOG INC | $4,086,000 | – | 40,000 | +100.0% | 2.07% | – |
| AXGT | New | AXOVANT SCIENCES LTD | $4,043,000 | – | 875,000 | +100.0% | 2.05% | – |
| ROKU | New | ROKU INC | $3,776,000 | – | 20,000 | +100.0% | 1.92% | – |
| DMAC | Buy | DIAMEDICA THERAPEUTICS INC | $3,095,000 | +121.9% | 730,000 | +262.7% | 1.57% | +73.6% |
| New | AURYN RESOURCES RESTRICTEDstock | $2,252,000 | – | 1,500,000 | +100.0% | 1.14% | – | |
| CMRX | New | CHIMERIX INC | $122,000 | – | 49,085 | +100.0% | 0.06% | – |
| RWT | Exit | REDWOOD TR INC | $0 | – | -75,000 | -100.0% | -0.34% | – |
| PIRS | Exit | PIERIS PHARMACEUTICALS INC | $0 | – | -270,000 | -100.0% | -0.54% | – |
| PAAS | Exit | PAN AMERN SILVER CORP | $0 | – | -30,000 | -100.0% | -0.59% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS IN | $0 | – | -40,000 | -100.0% | -1.12% | – |
| TSLA | Exit | TESLA INC | $0 | – | -2,000 | -100.0% | -1.40% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -460,000 | -100.0% | -3.88% | – |
| OCUL | Exit | OCULAR THERAPEUTIX INC | $0 | – | -720,000 | -100.0% | -3.89% | – |
| QURE | Exit | UNIQURE NV | $0 | – | -180,000 | -100.0% | -5.26% | – |
| SONO | Exit | SONOS INC | $0 | – | -1,570,000 | -100.0% | -14.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CUE BIOPHARMA INC | 8 | Q3 2021 | 26.7% |
| MAXAR TECHNOLOGIES INC | 7 | Q2 2021 | 41.3% |
| REATA PHARMACEUTICALS INC | 6 | Q2 2021 | 29.6% |
| REPLIMUNE GROUP INC | 5 | Q2 2021 | 12.1% |
| APTOSE BIOSCIENCES INC | 5 | Q4 2020 | 18.7% |
| CARDIFF ONCOLOGY INC | 5 | Q2 2021 | 9.5% |
| DIAMEDICA THERAPEUTICS INC | 5 | Q2 2021 | 2.9% |
| TFF PHARMACEUTICALS INC | 4 | Q3 2021 | 15.2% |
| INVESCO QQQ TR | 3 | Q3 2022 | 94.7% |
| LANTERN PHARMA INC | 3 | Q3 2021 | 13.5% |
View Corriente Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cardiff Oncology, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cue Biopharma, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| TFF Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| NAUTILUS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| Maxar Technologies Inc. | November 26, 2019 | 2,920,750 | 4.9% |
| CATABASIS PHARMACEUTICALS INC | February 23, 2018 | 1,692,899 | 7.3% |
| NEUROLOGIX INC/DE | February 14, 2011 | 16,858,224 | 37.7% |
| AMERICAN VANTAGE COMPANIESSold out | February 16, 2010 | 0 | 0.0% |
| AspenBio Pharma, Inc.Sold out | February 16, 2010 | 0 | 0.0% |
View Corriente Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-15 |
| SC 13G/A | 2022-02-14 |
View Corriente Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.